Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington Street, Boston, MA 02111, USA.
Nutr Metab (Lond). 2012 Feb 20;9(1):12. doi: 10.1186/1743-7075-9-12.
Despite plausible biological mechanisms, the differential abilities of phylloquinone (PK) and menaquinones (MKn) to prevent bone loss remain controversial. The objective of the current study was to compare the effects of PK, menaquinone-4 (MK-4) and menaquinone-7 (MK-7) on the rate of bone loss in ovariectomized (OVX) Norway rats. A secondary aim was to compare the effects of vitamin K with those of bisphosphonates (BP) on bone loss.
Rats (n = 96) were randomized to 6 dosing groups [n = 16/group; Sham; OVX; OVX + BP (100 μg/kg/100 μg/mL saline sc); OVX + PK; OVX + MK-4; and OVX + MK-7] for 6 wk. Equimolar daily doses of 107 mg PK/kg, 147 mg MK-4/kg, and 201 mg MK-7/kg diet were provided.
BP significantly increased bone strength and bone mineral density (BMD) vs. OVX (P < 0.05). However, PK, MK-4 or MK-7 did not change bone strength or BMD compared to the OVX group. Whereas supplementation of PK, MK-4 and MK-7 increased serum and tibia concentrations of each respective form, PK concentrations were consistently higher despite equimolar intakes.
PK, MK-4, and MK-7 do not appear to prevent bone loss in OVX rats when administered concurrent with adequate intake of other nutrients.
尽管有合理的生物学机制,但叶绿醌(PK)和甲萘醌(MKn)预防骨质流失的能力差异仍存在争议。本研究的目的是比较 PK、甲萘醌-4(MK-4)和甲萘醌-7(MK-7)对去卵巢(OVX)挪威大鼠骨质流失率的影响。次要目的是比较维生素 K 与双膦酸盐(BP)对骨质流失的影响。
将大鼠(n = 96)随机分为 6 个给药组[每组 n = 16;Sham;OVX;OVX + BP(100 μg/kg/100 μg/mL 生理盐水 sc);OVX + PK;OVX + MK-4;和 OVX + MK-7],给药 6 周。每日给予等摩尔剂量的 107 mg PK/kg、147 mg MK-4/kg 和 201 mg MK-7/kg 饮食。
BP 与 OVX 相比,显著增加骨强度和骨矿物质密度(BMD)(P < 0.05)。然而,与 OVX 组相比,PK、MK-4 或 MK-7 并未改变骨强度或 BMD。尽管 PK、MK-4 和 MK-7 的补充增加了血清和胫骨中各自形式的浓度,但 PK 浓度始终更高,尽管摄入量相等。
当与其他充足的营养素同时给予时,PK、MK-4 和 MK-7 似乎不能预防 OVX 大鼠的骨质流失。